ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has earned a consensus broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company. ESSA Pharma’s rating score has declined by 67% in the last three months as a result of a number of analysts’ ratings changes.

Brokerages have set a 12-month consensus price objective of $5.10 for the company and are predicting that the company will post ($0.18) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 100 out of 265 based on the ratings given to related companies.

Several equities analysts have recently weighed in on the company. Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Zacks Investment Research cut ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Bloom Burton cut ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Finally, ValuEngine cut ESSA Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 7th.

ESSA Pharma (EPIX) traded down 2.16% during mid-day trading on Thursday, hitting $0.29. 95,800 shares of the stock were exchanged. ESSA Pharma has a 12-month low of $0.26 and a 12-month high of $2.69. The stock’s market capitalization is $8.44 million. The firm has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.29.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with's FREE daily email newsletter.